2025 ISAKOS Biennial Congress ePoster
Autologous Bone Marrow Mesenchymal Stem Cells in Chronic Achilles Tendon Ruptures. Prospective Case Series.
Rafael Arriaza-Loureda, MD, PhD, Perillo, Oleiros, La Coruña SPAIN
Robert Soler-Rich, MD, Barcelona SPAIN
Gil Rodas, MD, Barcelona, Barcelona SPAIN
Lluis Orozco, MD, Barcelona, Barcelona SPAIN
Instituto de Terapia Regenerativa Tisular, Barcelona, SPAIN
The FDA has not cleared the following pharmaceuticals and/or medical device for the use described in this presentation. The following pharmaceuticals and/or medical device are being discussed for an off-label use: Instituto Terapia Regenerativa Tisular, Cultured Mesenchimal Stem Cells
Summary
A series of patients with chronic Achilles tendon rupture treated non-surgically, via percutaneous injection of ex vivo culture-expanded autologous bone marrow mesenchymal stem cells is presented. Results show that it is technically and clinically feasible, as well as being safe and able to to regenerate tendon tissue in such cases. All patients reached excellent result without complications
ePosters will be available shortly before Congress
Abstract
BACKGROUND. Management of chronic Achilles tendon rupture (ATR) involves demanding surgery, use of grafts and prolonged rehabilitation.
STUDY DESIGN: Prospective case series
METHODS. Seven patients with image-confirmed symptomatic chronic ATR were treated non-surgically, with percutaneous injection of intratendinous culture-expanded aBM-MSCs [20(±2)x10 6 ] and immediate post-injection mobilization. The patients followed standard rehabilitation. We assessed pre- and post-treatment changes in tendon structure using magnetic resonance imaging, pain on the visual analog scale (VAS), Victorian Institute Sport Assessment (VISA-A) scores, and clinical complications at 12 and 24 months post-treatment.
RESULTS. The injection of aBM-MSC treatment was safe and well tolerated. Achilles tendon tissue regenerated in all patients by the last visit, and all recovered tendon function. aBM-MSCs reduced internal tendon swelling and fluid, as well as regenerated tissue and collagen fibers. Patients reported significantly reduced pain [median scores: VAS (-8.5), VAS sport (-9.7), and improved VISA-A (86.5)]. All patients returned to their pre-injury daily activities immediately and to recreational sports activities by four months post-injection.
CONCLUSION. The intratendinous injection of culture-expanded aBM-MSCs is feasible and safe and should be considered a promising option in the personalized treatment of chronic ATR. Randomized clinical trials are needed to substantiate these results